Q2 2025 EPS Estimates for Haemonetics Co. (NYSE:HAE) Decreased by Zacks Research

Haemonetics Co. (NYSE:HAE) – Investment analysts at Zacks Research cut their Q2 2025 earnings per share (EPS) estimates for Haemonetics in a research note issued on Monday, October 7th. Zacks Research analyst R. Department now expects that the medical instruments supplier will earn $1.09 per share for the quarter, down from their previous forecast of $1.10. The consensus estimate for Haemonetics’ current full-year earnings is $4.57 per share. Zacks Research also issued estimates for Haemonetics’ Q3 2026 earnings at $1.28 EPS and FY2026 earnings at $5.15 EPS.

A number of other brokerages have also commented on HAE. BTIG Research started coverage on Haemonetics in a research report on Tuesday, September 10th. They set a “buy” rating and a $112.00 price objective for the company. Barrington Research restated an “outperform” rating and set a $108.00 price objective on shares of Haemonetics in a research report on Monday, September 23rd. Citigroup decreased their price objective on Haemonetics from $94.00 to $85.00 and set a “neutral” rating for the company in a research report on Thursday, August 22nd. JMP Securities reiterated a “market outperform” rating and set a $125.00 price target on shares of Haemonetics in a report on Tuesday, August 13th. Finally, Bank of America began coverage on Haemonetics in a report on Wednesday, September 11th. They set a “neutral” rating and a $85.00 price target for the company. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, Haemonetics presently has an average rating of “Moderate Buy” and a consensus target price of $106.14.

Haemonetics Trading Down 2.2 %

Shares of NYSE HAE opened at $74.45 on Wednesday. Haemonetics has a one year low of $70.74 and a one year high of $97.97. The firm has a market capitalization of $3.79 billion, a PE ratio of 32.51, a PEG ratio of 1.19 and a beta of 0.30. The company has a current ratio of 3.76, a quick ratio of 2.33 and a debt-to-equity ratio of 1.35. The business has a 50-day moving average price of $76.95 and a two-hundred day moving average price of $83.98.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported $1.02 earnings per share for the quarter, missing the consensus estimate of $1.03 by ($0.01). Haemonetics had a net margin of 8.61% and a return on equity of 21.86%. The firm had revenue of $336.17 million during the quarter, compared to analyst estimates of $335.08 million. During the same quarter last year, the company earned $1.05 EPS. The company’s quarterly revenue was up 8.0% compared to the same quarter last year.

Insider Transactions at Haemonetics

In related news, insider Stewart W. Strong sold 4,312 shares of the business’s stock in a transaction on Friday, July 26th. The stock was sold at an average price of $91.15, for a total value of $393,038.80. Following the sale, the insider now owns 18,196 shares of the company’s stock, valued at $1,658,565.40. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.80% of the stock is owned by insiders.

Institutional Investors Weigh In On Haemonetics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Capital Research Global Investors raised its position in shares of Haemonetics by 2.3% during the first quarter. Capital Research Global Investors now owns 6,674,751 shares of the medical instruments supplier’s stock worth $569,690,000 after acquiring an additional 151,183 shares during the last quarter. Vanguard Group Inc. increased its holdings in Haemonetics by 0.5% in the fourth quarter. Vanguard Group Inc. now owns 5,406,309 shares of the medical instruments supplier’s stock valued at $462,293,000 after purchasing an additional 25,451 shares during the last quarter. Wellington Management Group LLP increased its holdings in Haemonetics by 3.2% in the fourth quarter. Wellington Management Group LLP now owns 3,268,083 shares of the medical instruments supplier’s stock valued at $279,454,000 after purchasing an additional 101,029 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in Haemonetics by 6.3% in the second quarter. Dimensional Fund Advisors LP now owns 978,735 shares of the medical instruments supplier’s stock valued at $80,972,000 after purchasing an additional 57,665 shares during the last quarter. Finally, Thrivent Financial for Lutherans increased its holdings in Haemonetics by 6,573.6% in the second quarter. Thrivent Financial for Lutherans now owns 849,350 shares of the medical instruments supplier’s stock valued at $70,267,000 after purchasing an additional 836,623 shares during the last quarter. Institutional investors own 99.67% of the company’s stock.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.